MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)

Source :: Legal Monitor Worldwide. October 20, 2020
Publication Year :: 2020
Abstract: MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC. (Janssen) has announced it received a positive opinion [...]

Subjects :: MorphoSys AG
Guselkumab
Biotechnology industries
Psoriatic arthritis -- Care and treatment
Biological products industry
Antiarthritic agents
Adults
Business, international
Law
European Union
Tremfya (Medication)

Tools